Angiotensin II 2.5mg/1ml solution for infusion vials

Overdose with angiotensin II would be expected to result in hypertension, necessitating close monitoring and supportive care [FDA Label]. Effects are also expected to be brief as the half-life of angiotensin II is less than one minute [FDA Label].

In the ATHOS-3 clinical study there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients. The major imbalance was in deep venous thromboses - which prompts the potential need to use concurrent venous thromboembolism (VTE) prohphylaxis [FDA Label].

Adverse effects of noticeable potential (>= 10%) include thromboembolic events (ie. like deep vein thrombosis) including arterial and venous thrombotic events, thrombocytopenia, tachycardia, and fungal infection.

Effects whose potential are < 10% include delirium, acidosis, hyperglycemia, peripheral ischemia [FDA Label].

Concomitant use of angiotensin converting enzymes (ACE) inhibitors may increase the response of angiotensin II [FDA Label].

Concomitant use of angiotensin II blockers (ARBs) may decrease the response to angiotensin II [FDA Label].

There are no formal data regarding the safe use of angiotensin II in pregnant women. However, septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or otherdistributive shock is likely to increase the risk of maternal and fetal morbidity and mortality [FDA Label].

There is no formal data regarding whether or not angiotensin II may become present in human milk and there is no data available on the effects of angiotensin II on the breastfed child or the effects on milk production [FDA Label].

The safety and efficacy of angiotensin II in pediatric patients has not yet been established [FDA Label].

There is no difference in the safety or efficacy between patients less than 65 years old and those 65 years or older when treated with angiotensin II [FDA Label].

There is no difference in pharmacokinetics between male and female patients [FDA Label].

The pharmacokinetics of angiotensin II are not expected to be influenced by renal impairment or hepatic impairment [FDA Label].